Merck & Co spin off could start a trend in big pharma

Merck & Co’s strategy to spin off its older drugs and biosimilars into a new stand-alone business will be closely watched by other pharma companies considering the same move, analysts h

Merck to spin old drugs into ‘NewCo’ focused on generics, wo...

Chasing Astellas, UK's KaNDy heads to phase 3 with menopause...

UK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial showed it reduced hot flashes as well as improved quality of life, setting

Apple launches Research app, along with three health studies

AMAG bags FDA okay for second ‘female Viagra’ drug

Allergan abandons women’s health sale plan as profit slumps

Shares in Allergan fell after the company said it had swung to a loss in the last quarter of 2018, and forecast 2019 revenues below analyst expectations.